Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 7, 2015, Pages 1603-1611

  Jo, Dong Hyun ^a,b   Kim, Jin Hyoung ^a   Lee, Tae Geol ^c   Kim, Jeong Hun ^a,b  

^a Seoul National University Biomedical Research Institute   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Research Institute of Standards and Science   (South Korea)

Author keywords

Blood neural barriers; CNS disease; Drug delivery systems; Nanoparticle design; Nanoparticles

Indexed keywords

BLOOD; CONTROLLED DRUG DELIVERY; NANOPARTICLES; NEUROPHYSIOLOGY; OPHTHALMOLOGY; PARTICLE SIZE; SURFACE CHARGE;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; DRUG DELIVERY SYSTEM; MONONUCLEAR PHAGOCYTE SYSTEMS; OVERALL PROCESS; PARTICLE SIZE AND SHAPE; PHYSICAL BARRIERS; THERAPEUTIC EFFECTS;

TARGETED DRUG DELIVERY;

NANOPARTICLE;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; BLINDNESS; BLOOD; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; BODY FLUID; BRAIN DISEASE; BRAIN INFARCTION; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MONONUCLEAR PHAGOCYTE; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; RETINA DEGENERATION; RETINA DISEASE; RETINITIS PIGMENTOSA; RETROLENTAL FIBROPLASIA; REVIEW; STARGARDT DISEASE; SURFACE CHARGE; TARGET CELL; THERAPY EFFECT; UVEITIS; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; NANOMEDICINE; PARTICLE SIZE; PATHOLOGY; RETINAL DISEASES;

BLOOD-BRAIN BARRIER; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; RETINAL DISEASES;

EID: 84942108229     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.04.015     Document Type: Review

References (99)

1. Kim J.H., Kim J.H., Kim K.W., Kim M.H., Yu Y.S. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009, 20:505101.
2. Staquicini F.I., Ozawa M.G., Moya C.A., Driessen W.H., Barbu E.M., Nishimori H., et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 2011, 121:161-173.
3. Ganesh S., Iyer A.K., Gattacceca F., Morrissey D.V., Amiji M.M. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release 2013, 172:699-706.
4. Schwartz S.G., Scott I.U., Flynn H.W., Stewart M.W. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv 2014, 11:61-68.
5. Kong L., Cai X., Zhou X., Wong L.L., Karakoti A.S., Seal S., et al. Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol Dis 2011, 42:514-523.
6. Arvizo R.R., Saha S., Wang E., Robertson J.D., Bhattacharya R., Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A 2013, 110:6700-6705.
7. Kim J.H., Kim M.H., Jo D.H., Yu Y.S., Lee T.G., Kim J.H. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 2011, 32:1865-1871.
8. Jo D.H., Kim J.H., Yu Y.S., Lee T.G., Kim J.H. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomedicine 2012, 8:784-791.
9. Kalishwaralal K., Banumathi E., Ram Kumar Pandian S., Deepak V., Muniyandi J., Eom S.H., et al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf B Biointerfaces 2009, 73:51-57.
10. Jo D.H., Lee T.G., Kim J.H. Nanotechnology and nanotoxicology in retinopathy. Int J Mol Sci 2011, 12:8288-8301.
11. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
12. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
13. Sau T.K., Rogach A.L. Nonspherical noble metal nanoparticles: colloid-chemical synthesis and morphology control. Adv Mater 2010, 22:1781-1804.
14. Sau T.K., Rogach A.L., Jackel F., Klar T.A., Feldmann J. Properties and applications of colloidal nonspherical noble metal nanoparticles. Adv Mater 2010, 22:1805-1825.
15. Euliss L.E., DuPont J.A., Gratton S., DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev 2006, 35:1095-1104.
16. Tenzer S., Docter D., Rosfa S., Wlodarski A., Kuharev J., Rekik A., et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011, 5:7155-7167.
17. Arvizo R.R., Rana S., Miranda O.R., Bhattacharya R., Rotello V.M., Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine 2011, 7:580-587.
18. Zhao F., Zhao Y., Liu Y., Chang X., Chen C., Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7:1322-1337.
19. Duan X., Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 2013, 9:1521-1532.
20. Kudgus R.A., Szabolcs A., Khan J.A., Walden C.A., Reid J.M., Robertson J.D., et al. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One 2013, 8:e57522.
21. Muthu M.S., Leong D.T., Mei L., Feng S.S. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4:660-677.
22. Kim J.H., Kim J.H., Park J.A., Lee S.W., Kim W.J., Yu Y.S., et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006, 39:339-345.
23. Kuang Y., An S., Guo Y., Huang S., Shao K., Liu Y., et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 2013, 454:11-20.
24. Zhang B., Sun X., Mei H., Wang Y., Liao Z., Chen J., et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials 2013, 34:9171-9182.
25. Gao H., Yang Z., Zhang S., Cao S., Shen S., Pang Z., et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013, 3:2534.
26. Lei C., Cui Y., Zheng L., Chow P.K., Wang C.H. Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects. Biomaterials 2013, 34:7483-7494.
27. Kurakhmaeva K.B., Djindjikhashvili I.A., Petrov V.E., Balabanyan V.U., Voronina T.A., Trofimov S.S., et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009, 17:564-574.
28. Pilakka-Kanthikeel S., Atluri V.S., Sagar V., Saxena S.K., Nair M. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One 2013, 8:e62241.
29. Veronesi M.C., Aldouby Y., Domb A.J., Kubek M.J. Thyrotropin-releasing hormone d, l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo. Brain Res 2009, 1303:151-160.
30. Sun W., Xie C., Wang H., Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004, 25:3065-3071.
31. Tiwari M.N., Agarwal S., Bhatnagar P., Singhal N.K., Tiwari S.K., Kumar P., et al. Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic Biol Med 2013, 65:704-718.
32. Liu Z., Jiang M., Kang T., Miao D., Gu G., Song Q., et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013, 34:3870-3881.
33. An S., Kuang Y., Shen T., Li J., Ma H., Guo Y., et al. Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury. Biomaterials 2013, 34:8949-8959.
34. Yun X., Maximov V.D., Yu J., Zhu H., Vertegel A.A., Kindy M.S. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab 2013, 33:583-592.
35. Takamiya M., Miyamoto Y., Yamashita T., Deguchi K., Ohta Y., Ikeda Y., et al. Neurological and pathological improvements of cerebral infarction in mice with platinum nanoparticles. J Neurosci Res 2011, 89:1125-1133.
36. Kim C.K., Kim T., Choi I.Y., Soh M., Kim D., Kim Y.J., et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl 2012, 51:11039-11043.
37. Jo D.H., Kim J.H., Lee T.G., Kim J.H. Nanoparticles in the treatment of angiogenesis-related blindness. J Ocul Pharmacol Ther 2013, 29:135-142.
38. Cai X., Conley S.M., Nash Z., Fliesler S.J., Cooper M.J., Naash M.I. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010, 24:1178-1191.
39. Cai X., Sezate S.A., Seal S., McGinnis J.F. Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria. Biomaterials 2012, 33:8771-8781.
40. Chen J., Patil S., Seal S., McGinnis J.F. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006, 1:142-150.
41. Cai X., Seal S., McGinnis J.F. Sustained inhibition of neovascularization in vldlr-/- mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF-kappaB pathway. Biomaterials 2014, 35:249-258.
42. Kyosseva S.V., Chen L., Seal S., McGinnis J.F. Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice. Exp Eye Res 2013, 116:63-74.
43. Jo D.H., Kim J.H., Son J.G., Piao Y., Lee T.G., Kim J.H. Inhibitory activity of gold and silica nanospheres to VEGF-mediated angiogenesis is determined by their sizes. Nano Res 2014, 7:844-852.
44. Jo D.H., Kim J.H., Son J.G., Song N.W., Kim Y.I., Yu Y.S., et al. Anti-angiogenic effect of bare titanium dioxide nanoparticles on pathologic neovascularization without unbearable toxicity. Nanomedicine 2014, 10:1109-1117.
45. Pan Y., Ding H., Qin L., Zhao X., Cai J., Du B. Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. J Biomed Nanotechnol 2013, 9:1746-1756.
46. Pan Y., Wu Q., Liu R., Shao M., Pi J., Zhao X., et al. Inhibition effects of gold nanoparticles on proliferation and migration in hepatic carcinoma-conditioned HUVECs. Bioorg Med Chem Lett 2014, 24:679-684.
47. Kim H., Csaky K.G. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J Control Release 2010, 142:286-293.
48. Singh S.R., Grossniklaus H.E., Kang S.J., Edelhauser H.F., Ambati B.K., Kompella U.B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009, 16:645-659.
49. Jin J., Zhou K.K., Park K., Hu Y., Xu X., Zheng Z., et al. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci 2011, 52:6230-6237.
50. Lu Y., Zhou N., Huang X., Cheng J.W., Li F.Q., Wei R.L., et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol 2014, 7:1-7.
51. de Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.C., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712.
52. Sakai T., Kohno H., Ishihara T., Higaki M., Saito S., Matsushima M., et al. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006, 82:657-663.
53. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
54. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
55. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
56. Yang S.T., Luo J., Zhou Q., Wang H. Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes. Theranostics 2012, 2:271-282.
57. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
58. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
59. Lu F., Wu S.H., Hung Y., Mou C.Y. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 2009, 5:1408-1413.
60. Yuan Y., Liu C., Qian J., Wang J., Zhang Y. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomaterials 2010, 31:730-740.
61. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
62. Schipper M.L., Iyer G., Koh A.L., Cheng Z., Ebenstein Y., Aharoni A., et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.
63. Yue Z.G., Wei W., Lv P.P., Yue H., Wang L.Y., Su Z.G., et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules 2011, 12:2440-2446.
64. Xiao K., Li Y., Luo J., Lee J.S., Xiao W., Gonik A.M., et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
65. Kelf T.A., Sreenivasan V.K., Sun J., Kim E.J., Goldys E.M., Zvyagin A.V. Non-specific cellular uptake of surface-functionalized quantum dots. Nanotechnology 2010, 21:285105.
66. Tenzer S., Docter D., Kuharev J., Musyanovych A., Fetz V., Hecht R., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013, 8:772-781.
67. Zahr A.S., Davis C.A., Pishko M.V. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 2006, 22:8178-8185.
68. Dellian M., Yuan F., Trubetskoy V.S., Torchilin V.P., Jain R.K. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000, 82:1513-1518.
69. Kim B., Han G., Toley B.J., Kim C.K., Rotello V.M., Forbes N.S. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol 2010, 5:465-472.
70. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 121:3-9.
71. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
72. Cossart P. Host/pathogen interactions. Subversion of the mammalian cell cytoskeleton by invasive bacteria. J Clin Invest 1997, 99:2307-2311.
73. Arnida, Janat-Amsbury M.M., Ray A., Peterson C.M., Ghandehari H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm 2011, 77:417-423.
74. Qiu Y., Liu Y., Wang L., Xu L., Bai R., Ji Y., et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 2010, 31:7606-7619.
75. Decuzzi P., Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006, 27:5307-5314.
76. Decuzzi P., Lee S., Bhushan B., Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng 2005, 33:179-190.
77. Doshi N., Prabhakarpandian B., Rea-Ramsey A., Pant K., Sundaram S., Mitragotri S. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release 2010, 146:196-200.
78. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
79. Jo D.H., Kim J.H., Kim J.H. How to overcome diabetic retinopathy: focusing on blood-retinal barrier. Immunol Endocrinol Metab Agents Med Chem 2012, 12:110-117.
80. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
81. Biddlestone-Thorpe L., Marchi N., Guo K., Ghosh C., Janigro D., Valerie K., et al. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv Drug Deliv Rev 2012, 64:605-613.
82. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010, 99:1654-1673.
83. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009, 379:146-157.
84. Lim Y., Jo D.H., Kim J.H., Ahn J.H., Hwang Y.K., Kang D.K., et al. Human apolipoprotein(a) kringle V inhibits ischemia-induced retinal neovascularization via suppression of fibronectin-mediated angiogenesis. Diabetes 2012, 61:1599-1608.
85. Mains J., Wilson C.G. The vitreous humor as a barrier to nanoparticle distribution. J Ocul Pharmacol Ther 2013, 29:143-150.
86. Xu Q., Boylan N.J., Suk J.S., Wang Y.Y., Nance E.A., Yang J.C., et al. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J Control Release 2013, 167:76-84.
87. Kim H., Robinson S.B., Csaky K.G. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 2009, 26:329-337.
88. Koo H., Moon H., Han H., Na J.H., Huh M.S., Park J.H., et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012, 33:3485-3493.
89. Yang S.T., Liu Y., Wang Y.W., Cao A. Biosafety and bioapplication of nanomaterials by designing protein-nanoparticle interactions. Small 2013, 9:1635-1653.
90. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
91. Lundqvist M., Stigler J., Cedervall T., Berggard T., Flanagan M.B., Lynch I., et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 2011, 5:7503-7509.
92. Lynch I., Salvati A., Dawson K.A. Protein-nanoparticle interactions: what does the cell see?. Nat Nanotechnol 2009, 4:546-547.
93. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release 2012, 161:164-174.
94. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992, 267:18759-18765.
95. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
96. Podila R., Brown J.M. Toxicity of engineered nanomaterials: a physicochemical perspective. J Biochem Mol Toxicol 2013, 27:50-55.
97. Cedervall T., Lynch I., Lindman S., Berggard T., Thulin E., Nilsson H., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A 2007, 104:2050-2055.
98. Chakraborty S., Joshi P., Shanker V., Ansari Z.A., Singh S.P., Chakrabarti P. Contrasting effect of gold nanoparticles and nanorods with different surface modifications on the structure and activity of bovine serum albumin. Langmuir 2011, 27:7722-7731.
99. Gagner J.E., Lopez M.D., Dordick J.S., Siegel R.W. Effect of gold nanoparticle morphology on adsorbed protein structure and function. Biomaterials 2011, 32:7241-7252.